Regulatory Approvals, Launch of Products and Services, Preliminary Clinical Data, and Acquisitions - Research Report on St. Jude Medical, PAREXEL, ViroPharma, MEDNAX, and IPC
NEW YORK, July 2, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Wall Street Reports announced new research reports highlighting St. Jude Medical, Inc. (NYSE: STJ), PAREXEL International Corporation (NASDAQ: PRXL), ViroPharma Inc. (NASDAQ: VPHM), MEDNAX Inc. (NYSE: MD), and IPC The Hospitalist Company Inc. (NASDAQ: IPCM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
St. Jude Medical, Inc. Research Report
On June 27, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced the regulatory approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) and launch of the Accent MRI Pacemaker and the Tendril MRI lead. According to the Company, the Accent MRI Pacemaker is the only commercially available system with labeling that allows patients to undergo full-body, high-resolution magnetic resonance imaging (MRI) scans to accommodate their current and future medical needs. William Phillips, Senior Vice President of St. Jude Medical Asia, said, "The sophisticated pacemaker functionality and labeling of full-body MRI scans are especially important for patients who may need an MRI scan in the chest and abdominal area." The Company reported that the Accent MRI DR Pacemaker, available in two different models, is a dual chamber pacemaker that can sense and pace in the atrium and ventricle (the upper and lower chambers) of the right side of the heart, while the Accent MRI SR pacemaker is a single chamber pacemaker that can sense and pace in the right ventricle, the lower right chamber of the heart. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/bf35_STJ]
--
PAREXEL International Corporation Research Report
On June 24, 2013, PAREXEL International Corporation (PAREXEL) announced the launch of PAREXEL Functional Services within the Company's Clinical Research Services business segment. PAREXEL stated that it has established the unit to offer solutions for customers interested in outsourcing particular functions rather than full development programs in the clinical development process. According to the Company, the unit will provide clinical operations, data management, biostatistics, and medical writing, among others. PAREXEL may offer these services through a range of engagement models including insourcing/staffing, full functional outsourcing, as well as optimized solutions. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/037f_PRXL]
--
ViroPharma Inc. Research Report
On June 27, 2013, ViroPharma Inc. (ViroPharma) announced updated data from two ongoing Phase 2 dose ranging studies investigating maribavir for both first line treatment of cytomegalovirus (CMV) and treatment of resistant/refractory CMV. The Company said that preliminary virology data are available from 83 subjects, who have been followed for at least three weeks (52 in the "asymptomatic" CMV viremia treatment study and 31 in the U.S. resistant/refractory CMV treatment study). ViroPharma revealed that in the asymptomatic CMV viremia study, among 39 subjects receiving maribavir (all dose combined), 36 (92%) achieved plasma CMV DNA levels below the quantification limited (BQL) during therapy, one subject failed to achieve BQL while on therapy, and two subjects had withdrawn for non-virologic reasons prior to achieving BQL. Two of the 36 subjects who achieved BQL subsequently, experienced a virologic breakthrough (detectable plasma CMV DNA at any level, even if level returned to BQL at later visits) while on treatment. On the other hand, in the study of resistant/refractory CMV, among 39 subjects receiving maribavir (all doses combined), the Company revealed that 26 (84%) achieved BQL during therapy, four subjects failed to achieve BQL while on therapy, and one subject had withdrawn for non-virologic reasons prior to achieving BQL. 11 of the 26 subjects who achieved BQL subsequently experienced virologic breakthrough while on treatment. The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/cf37_VPHM]
--
MEDNAX Inc. Research Report
On June 27, 2013, MEDNAX Inc. (MEDNAX) announced the acquisition of Neonatal Intensive Care Associates, a neonatal physician group practice based in Lubbock, Texas. The acquired group practice consists of three neonatologists who provide a wide spectrum of services, including neonatal intensive care, labor and delivery, newborn nursery, and maternal consults at Covenant Women & Children's Hospital. According to the Company, the practice will become a part of its Pediatrix Medical Group division, a national group practice consisting of the nation's leading neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians. MEDNAX stated that the practice was acquired for cash and the transaction is expected to be immediately accretive to earnings. Additional terms of the transaction were not disclosed. The Full Research Report on MEDNAX Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/661d_MD]
--
IPC The Hospitalist Company Inc. Research Report
On June 26, 2013, IPC The Hospitalist Company Inc. (IPC) announced that it has acquired Sound Senior Geriatrics LLC (SSG), a post-acute hospitalist practice based in Mystic, Connecticut. Commenting on the acquisition, R. Jeffrey Taylor, President and Chief Operating Officer of IPC, said, "This acquisition will enable our practices to improve the integration of care and ultimately the outcomes for both the patients and the facilities we serve." IPC stated that the acquisition represents the Company's expansion in Southern New England, where it already has an established presence. The Full Research Report on IPC The Hospitalist Company Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d20b_IPCM]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports
Share this article